focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The results were better than expected and the writedown was expected. Record cashflow from operations, up 51% to $443 million from $293 million � Net debt reduced to $546 million from $697 million and healthy leverage ratios maintained The writedown of $1,070 million seems very high.They have basically writen off the $647m cash they paid for Roxanne and c.$300m in value of the 40m shares they issued. The NAV now booked as Net at 31 December 2017 at $1,528 million, compared to $2,411 million at 31 December 2016.
R U CRAZY?
day trading only.. I like the company so will go long at some point. Just good business (If it works for you) I've traded 11 times today and took 3 losses. Im out for now, so will go long once it stablises
day trading only.. I like the company so will go long at some point. Just good business (If it works for you) I've traded 11 times today and took 3 losses. Im out for now, so will go long once it stablises
It looks like the big boys are playing poker with each other. Who will cave in?
Why would you open a short today when all the bad news is out of the way and there will no surprises for quite some time now. Dividend has increased slightly, new CEO now in place and a very real prospect of being subject to a takeover bid.
Just opened second short at 960 @ �50pp so this is a day traders stock today
good luck foxy. you are brave to open a short now... it's way too volatile at the moment and could go either way imo
Market seems to like the results. All negative news already priced in presumably.
Market seems to like the results. All negative news already priced in presumably.
SP has risen sharply on what looks at first sight to be a poor set of results, especially a huge loss. The loss was due to the devaluation of the Generic side of the business--remember what i said about the new CEO getting bad news out of the way at the beginning. That aside the business has been quite resilient in a challenging market place and with a new CEO in place hopefully 2018 will start to see an improvement.
as I think this will tank now. Only a small �50 pp
Took a while but to volatile for me
So, we have already had an update on the generic version of the Advair drug. It may be that growth in the injectable division and branded franchises will help performance. An improvement in branded sales should be seen, as shipment delays and the devaluation of the Egyptian pound seen in the first half wear off. A rally will target 10.82 and then 11.60.
.......except that the news of continued delays on the Advair generic is surely already priced in?
have you not seen the RNS this morning? i think that will nullify that small bit of good news?
Article in yesterday’s telegraph identifying hikma as a potential takeover target
My last posting is a copy of a news article about Hikma.
Is Hikma Pharmaceuticals still cheap? Great news for investors – Hikma Pharmaceuticals is still trading at a fairly cheap price. My valuation model shows that the intrinsic value for the stock is £14.51, but it is currently trading at UK£8.95 on the share market, meaning that there is still an opportunity to buy now. Another thing to keep in mind is that Hikma Pharmaceuticals’s share price is quite stable relative to the rest of the market, as indicated by its low beta. This means that if you believe the current share price should move towards its intrinsic value over time, a low beta could suggest it is not likely to reach that level anytime soon, and once it’s there, it may be hard to fall back down into an attractive buying range again. What does the future of Hikma Pharmaceuticals look like? LSE:HIK Future Profit Mar 2nd 18 LSE:HIK Future Profit Mar 2nd 18 Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. Hikma Pharmaceuticals’s earnings over the next few years are expected to increase by 26.94%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value. What this means for you: Are you a shareholder? Since HIK is currently undervalued, it may be a great time to increase your holdings in the stock. With a positive outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as financial health to consider, which could explain the current undervaluation. Are you a potential investor? If you’ve been keeping an eye on HIK for a while, now might be the time to make a leap. Its buoyant future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy HIK. But before you make any investment decisions, consider other factors such as the strength of its balance sheet, in order to make a well-informed investment decision. Price is just the tip of the iceberg. Dig deeper into what truly matters – the fundamentals – before you make a decision on Hikma Pharmaceuticals. You can find everything you need to know about Hikma Pharmaceuticals in the latest infographic research report. If you are no longer interested in Hikma Pharmaceuticals, you can use our free platform to see my list of over 50 other stocks with a high growth potential. Copied from news article
I topped up a few on the drop today...as long as the results show that the BOD are managing the current issues then that will be good for when the sector improves overall.....the company isnt going bankrupt or in any financial stress...so it is really a matter of patience and making the right business decisions for the future.
The low today took the Mcap below �2 billion... will that satisfy the market's valuation of Hikma? 240.68m shares in issue... divided by 3 gets 802p a share... reasonable value? Recent high of 1159 (daily chart) minus a third 772.6... is that bargain territory? Something has to signal the bottom.
Unbelievably the SP has totally reversed this mornings fall and is now (as i write) slightly up on yesterday's close. Barclays had a double downgrade on Hikma but they did say that the appointment of the new CEO was a positive thing. We don't really have much option but to hope the new CEO does manage to turn this company around. Interestingly, dispite Hikma going on about a good pipeline of products only one has been announced this year so far and even that one has a very limited potential for sales. I just wonder if this is deliberate so they can allow the new CEO to start announcing a raft of new products just after the year end statement is made.
Personally, I think the market is expecting write downs within the generics acquisitions....the value on the books is currently too high, i suspect.... The new CEO clearly has to make decisions about the viability of certain factories and make cost cutting decisions....the question is how much will it cost ... Alternatively he is going to have to be a good judge on the turnaround of generic prices....something the current board got wrong, sadly The market is clearly saying to the BOD ...show us what you intend to do...to get the EPS back on track ...
Yes Jimbo, the results will be very interesting: how will the tension between the new CEO, wanting to "clear the decks", and the existing management, wanting to put a brave face on it, play out? As you say, Generics is not everything, nevertheless the new CEO presumably has a good track record of dealing with the FDA, on which Hikma are seeking to capitalise. So I think existing PIs just need to sit this one out: all you can say is that the SP should get back on track some time in 2018, but it will continue to be a rocky ride in the meantime. Trying to trade such a speculative share is a mug's game. But if it plumbs new lows, I might be tempted to top up, except I'm already overweight in this share, and there are limits. And what will turn out to be the final low point? I thought I'd found that at 1400...1200...1000...LOL!